NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

NMC Health: Citi initiates with a target price of 520p and a neutral rating.

3 Feb Investec 610.00 Buy

Update of group strategy.

////////////////////////////////////////////////////////////////////////////////////////////////

16 Feb Jefferies... 600.00 Buy

Full year results

Acquisition of Clinica Eugin
RNS
RNS Number : 6648F
NMC Health Plc
24 February 2015





24 February 2015

NMC HEALTH PLC ANNOUNCES THE ACQUISITION OF LEADING GLOBAL FERTILITY CENTRE

NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated private healthcare provider operating across the United Arab Emirates, is pleased to announce that it has entered into an agreement to acquire 86.4% of issued share capital of Clinica Eugin ('Eugin'), a leading global fertility treatment provider based in Barcelona, Spain, for an Enterprise Value of €143m. Eugin is one of the largest fertility clinics in Europe and the established leader in cross-border fertility treatment with patients from the largest Western European countries, as well as the MENA region. The shares are to be acquired from ProA Capital, Eugin's founders and members of the Eugin management team.

The acquisition of Eugin allows NMC to achieve several key elements of its recently updated Group Strategy and is supported by a strong strategic rationale:

· Eugin is a leading IVF centre of excellence with world-leading technology and expertise as well as strong brand recognition

· Brings leading global expertise and technologies in fertility services to NMC's network in the UAE and strongly complements existing NMC women's health services

· Accelerates the development of NMC into a centre of clinical excellence for women's health and will allow NMC to establish a foothold in the UAE medical tourism market

· Significant potential for revenue synergies from growing Eugin's franchise in the UAE and the broader GCC/MENA region

· Transaction expected to be significantly accretive in Year 1 with positive effect on margins and attractive ROIC

· Eugin's strong and experienced management team have agreed to remain at the Company, limiting potential integration risk

Furthermore, in line with NMC's Group Strategy, the Company is also in discussion with multiple parties regarding potential acquisition opportunities in the UAE and GCC region, which would allow NMC to increase its scale across the region as well as further maximise operational synergies. These discussions remain at a preliminary stage and there is no certainty that any of these discussions will lead to additional announced transactions.





Dr. B.R. Shetty, Chief Executive Officer, commented:

"The acquisition of Eugin represents a unique juncture in the history of NMC, combining the leading UAE hospital franchise with a leading global fertility franchise. This transaction offers NMC the opportunity to become the leading integrated women's health provider from fertility through obstetrics and paediatrics in the UAE, and also establishes a foothold for the Company in the growing medical tourism market. The acquisition is expected to be accretive within the first year, and further progresses NMC's strategy of creating centres of excellence across a number of clinical specialties".



Market Opportunity in the UAE fertility sector

Infertility is a growing medical issue within the UAE and, according to Frost & Sullivan ('F&S'), it is estimated that the total fertility rate (number of children per woman) in the country has declined from 2.7 in the year 2000 to 1.7 in 2010, with approximately one in six couples experiencing fertility problems. Furthermore, there is an acute shortage of world class fertility treatment facilities in the country with F&S estimating a supply/demand shortfall of 8,500 IVF cycles in 2013, which represented over 50% of the total demand for IVF treatment in that year.

The infertility market in the UAE is also expected to be driven by the growing medical tourism sector in Dubai. Dubai Health Authority has announced plans to attract 500,000 medical tourists by 2020, generating over $700m in revenues. As of 2014, infertility procedures have also been identified by Dubai Health Care City's (DHCC) recent survey as the leading treatment sought by medical tourists visiting the Emirate.



Information on Clinica Eugin

Based in Barcelona and founded in 1999, Eugin is amongst the largest European providers of fertility treatments, in terms of the number of cycles performed annually, and has the largest egg bank in Europe providing c.10% of donor IVF treatments in Europe. The Company is also the leader in cross-border fertility treatments in Europe. In 2014, the clinic treated more than 5,000 patients and carried out over 8,000 cycles. The clinic offers a full range of fertility treatments including intra-uterine insemination (IUI), in-vitro fertilisation (IVF), intra-cytoplasmic sperm injection (ICSI), fertility preservation and genetic screening.

Over 95% of Eugin's patients are referred from outside Spain with France (55%), Italy (17%), Switzerland (4%), MENA (3%) and the UK (2%) representing the main countries of origin for the patients. Almost all of Eugin's revenues are derived from privately insured or cash pay patients.

Eugin has been majority-owned by ProA Capital since 2010. Eugin's current senior management, Andres Rebage (General Operational Manager) and Dr. Valerie Vernaeve (General Medical Manager), have been with Eugin for several years and have agreed to continue to manage, and retain an investment, in the business.

For the twelve months ended 31 December 2014, Eugin reported revenues of €34.3m, EBITDA of €14.0m and EBITDA margins of 41.0%. As of 31 December 2014, Eugin had gross assets of €59.0m and approximately 230 employees.



Financing and Financial Impact on NMC

NMC will finance the transaction using existing cash and credit facilities. NMC expects to retain post transaction, a net debt to EBITDA level allowing the Company financial flexibility for future growth initiatives. In this transaction, NMC has not utilised any of the funds made available through the US$ 825m facility announced on 16 February 2015.

Excluding synergies, the transaction is expected to be significantly accretive to NMC's EPS.



Additional Information on the Transaction

The Transaction is subject to customary terms and conditions. The transaction was signed and closed simultaneously on 23 February, 2015.

HSBC is acting as Financial Advisor and Evercore Partners is acting as Strategic Advisor to NMC. In addition, NMC is being advised by Allen & Overy and PwC.

NMC Health plc will host a webcast and conference call presentation for investors and analysts today at 14.00 UK time. There will be a short presentation by management covering the FY 2014 results and this transaction followed by a Q&A session.



The call will be hosted by:

Mr Prasanth Manghat, Deputy CEO

Mr Suresh Krishnamoorthy, Chief Financial Officer

Mr Roy Cherry, Head of Strategy & IR







Date and time:

Date Tuesday 24 February 2014

Time 14.00 GMT (09.00 EDT, 18.00 UAE)









- ends -

24 Feb Investec N/A Buy
24 Feb Numis 620.00 Buy

25 Feb Jefferies... 800.00 Buy

Director/PDMR Shareholding
RNS
RNS Number : 9864F
NMC Health Plc
26 February 2015













NMC Health plc



NOTIFICATION MADE IN ACCORDANCE WITH RULE 3.1.4 (1) (a) OF THE

DISCLOSURE AND TRANSPARENCY RULES





London, 26 February 2015: NMC Health plc (LSE:NMC) ('NMC'), the leading integrated private sector healthcare operator in the United Arab Emirates, announces that it was notified on 26 February 2015 that the following director purchased ordinary shares of 10p each in the Company ("Shares"). The Shares were purchased at a price of 558 pence per Share.



Director
Position
No. of Shares purchased

Heather Lawrence
Independent Non-Executive Director
1,790




Following this purchase, Mrs Lawrence has an interest in a total of 6,347 Shares, representing approximately 0.01% of the issued share capital of the Company.

Naked Trader today - I've bought into NMC Health (LON:NMC)



I really like the middle east medcare sector at the moment. There is a massive catalyst for growth in that Dubai is rolling out mandatory healthcare insurance over the next couple of years which should see shares in NMC continue to rise - and also that of Al Noor which I bought last time and have a load of from lower.

The shares don't on the face of it look cheap - but remember the market looks forwards and it is eyeing up the benefits due from mandatory heathcare.

I think both NMC and ANH will boom (boom shake the room). (Tick, tick, tick.. boom...) (that's enough aged dance music references)

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 658.00. Over this period, the share price is up 19.54%.

18 Mar Numis 800.00 Buy

Two acquisitions

29 Apr Investec N/A Buy
29 Apr Numis 880.00 Buy

30 Apr Investec 900.00 Buy

5 May Jefferies... 1,000.00 Buy

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 869.50. Over this period, the share price is up 86.59%.

Acquisition of Pro Vita

Statement re Possible Offer
RNS
RNS Number : 8442B
Al Noor Hospitals Group PLC
09 October 2015



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION



THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER WILL BE MADE



FOR IMMEDIATE RELEASE

October 9th, 2015



The Board of Al Noor Hospitals Group Plc (the "Company") notes the recent media speculation in relation to the Company and confirms that it has received an approach from NMC Health Plc ("NMC") regarding a possible offer.



In accordance with Rule 2.6(a) of the Code, NMC is required, by not later than 5.00 p.m. on November 6th, 2015, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

NMC Health remains committed to a combination
StockMarketWire.com
NMC Health notes the announcement today by Al Noor Hospital Group and Mediclinic International Ltd.

"This confirms our belief in the competitiveness of our initial possible offer and that the combination of NMC and Al Noor has the strongest strategic and financial rationale for all stakeholders," it said in a statement.

"We reiterate our commitment to this opportunity despite the lack of meaningful engagement from the Board of Al Noor.

"We plan to issue a further announcement in due course. We would urge shareholders to take no action at this time."



At 9:22am:
(LON:ANH) Al Noor Hospitals Group PLC share price was +134p at 1128.5p
(LON:NMC) NMC Health PLC share price was +20p at 828.5p


Story provided by StockMarketWire.com

Company News

NMC Health abandons bid for Al Noor Hospitals

Mon, 16 November 2015




(ShareCast News) - NMC Health has abandoned its bid for Al Noor Hospitals, meaning South Africa's Mediclinic International looks set to clinch a deal with the Abu Dhabi-based healthcare operator.
Al Noor confirmed in early October that it had received an approach from NMC regarding a possible offer.

NMC said on Monday: "After a thorough assessment of the opportunity, NMC has concluded that the potential transaction would not deliver sufficient returns or shareholder value in line with its stated policy, and accordingly NMC now confirms that it does not intend to make an offer for Al Noor."

Last month, the boards of Al Noor and Mediclinic reached an agreement on the terms of a possible merger.

Under the proposed deal announced, Al Noor will acquire Mediclinic, with shareholders receiving 0.625 new shares for each Mediclinic share held.

The proposed deal will result in Mediclinic shareholders owning 84% to 93% of the enlarged group.

The groups said the merger will create a "leading international private healthcare group with deep operational expertise and a well-balanced geographic profile in Southern Africa, Switzerland and the United Arab Emirates".

At 1450 GMT, NMC Health shares were up 1.9% to 773.50p, while Al Noor was flat at 1,158p